Shopping Cart
Remove All
Your shopping cart is currently empty
β-Nicotinamide mononucleotide, reduced form disodium
(Synonyms: NMNH disodium) Copy Product Info
🥰Excellent
Synonyms: NMNH disodium
Catalog No. TN11626 Copy Product Info
Purity: 99.92%
🥰Excellent
β-Nicotinamide mononucleotide, reduced form disodium is the reduced form of β-nicotinamide mononucleotide with oral bioavailability. It significantly increases cellular NAD⁺ and NADH levels, inhibits glycolysis, the tricarboxylic acid cycle, and cell growth, and its efficacy depends on nicotinamide mononucleotide adenylyltransferase (NMNAT).
Cas No. 108347-85-9
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $35 | - | In Stock | |
| 5 mg | $74 | - | In Stock | |
| 10 mg | $106 | - | In Stock | |
| 25 mg | $173 | - | In Stock | |
| 50 mg | $256 | - | In Stock | |
| 100 mg | $378 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.92%
Appearance:Solid
Color:Yellow
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | β-Nicotinamide mononucleotide, reduced form disodium is the reduced form of β-nicotinamide mononucleotide with oral bioavailability. It significantly increases cellular NAD⁺ and NADH levels, inhibits glycolysis, the tricarboxylic acid cycle, and cell growth, and its efficacy depends on nicotinamide mononucleotide adenylyltransferase (NMNAT). |
| In vitro | Methods: HepG2 cells were treated with β-Nicotinamide mononucleotide, reduced form disodium, reduced form (NMNH) disodium; 100 μM was used for 12 h to detect NAD⁺ and metabolite levels, and 250–1000 μM was used for 12–72 h to detect cell growth and cell cycle. Results: 1 β-Nicotinamide mononucleotide, reduced form disodium, reduced form (NMNH) disodium (100 μM, 12 h) could significantly increase the intracellular NAD⁺ level in HepG2 cells and decrease the contents of glycolysis and tricarboxylic acid cycle intermediates [1]. 2 β-Nicotinamide mononucleotide, reduced form disodium, reduced form (NMNH) disodium (250–1000 μM, 12–72 h) could inhibit the proliferation of HepG2 cells and induce cell cycle arrest. |
| In vivo | Methods: Male mice were given a single administration of β-Nicotinamide mononucleotide, reduced form disodium, reduced form (NMNH) disodium: 340 mg/kg by intraperitoneal injection or intragastric administration, and 250 mg/kg by intraperitoneal injection, to detect NAD⁺ levels in various tissues. Results: 1 β-Nicotinamide mononucleotide, reduced form disodium, reduced form (NMNH) disodium (340 mg/kg, single intraperitoneal injection / intragastric administration) could increase the liver NAD⁺ level in male mice [1]. 2 β-Nicotinamide mononucleotide, reduced form disodium, reduced form (NMNH) disodium (250 mg/kg, single intraperitoneal injection) could increase the NAD⁺ levels in tissues such as liver, kidney, brain, muscle and whole blood of C57BL/6J mice by 2–5 times [2]. |
| Synonyms | NMNH disodium |
| Molecular Weight | 380.20 |
| Formula | C11H15N2Na2O8P |
| Cas No. | 108347-85-9 |
| Smiles | O[C@H]1[C@@H](O[C@H](COP([O-])([O-])=O)[C@H]1O)N2C=C(C(N)=O)CC=C2.[Na+].[Na+] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 80 mg/mL (210.42 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: β-Nicotinamide mononucleotide, reduced form disodium chemical structure | β-Nicotinamide mononucleotide, reduced form disodium in vivo | β-Nicotinamide mononucleotide, reduced form disodium in vitro | β-Nicotinamide mononucleotide, reduced form disodium formula | β-Nicotinamide mononucleotide, reduced form disodium molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.